Top segments and regional performance

Last year, the company generated ‪15.17 M‬ USD, the most of which — ‪9.86 M‬ USD — came from its top-performing segment, Immunotherapy, compared to ‪123.57 K‬ USD the previous year. The greatest contribution came from Australia, which accounted for ‪9.86 M‬ USD last year, with ‪123.57 K‬ USD the year before.